Basic Science with Preclinical Models to Investigate and Develop Liquid Biopsy: What Are the Available Data and Is It a Fruitful Approach?

The molecular analysis of circulating analytes (circulating tumor-DNA (ctDNA), -cells (CTCs) and -RNA (ctRNA)/exosomes) deriving from solid tumors and detected in the bloodstream-referred as liquid biopsy-has emerged as one of the most promising concepts in cancer management. Compelling data have ev...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2022-05, Vol.23 (10), p.5343
Main Authors: Cena, Benedetta, Melloul, Emmanuel, Demartines, Nicolas, Dormond, Olivier, Labgaa, Ismail
Format: Article
Language:English
Subjects:
Apoptosis
Biology
Biomarkers
Biopsy
Bone cancer
By products
Cancer therapies
Chemotherapy
circulating
Cloning
CTC
ctDNA
ctRNA
Ewings sarcoma
Exosomes
Kinases
Mutation
Plasma
Review
Science
Solid tumors
Translation
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The molecular analysis of circulating analytes (circulating tumor-DNA (ctDNA), -cells (CTCs) and -RNA (ctRNA)/exosomes) deriving from solid tumors and detected in the bloodstream-referred as liquid biopsy-has emerged as one of the most promising concepts in cancer management. Compelling data have evidenced its pivotal contribution and unique polyvalence through multiple applications. These data essentially derived from translational research. Therewith, data on liquid biopsy in basic research with preclinical models are scarce, a concerning lack that has been widely acknowledged in the field. This report aimed to comprehensively review the available data on the topic, for each analyte. Only 17, 17 and 2 studies in basic research investigated ctDNA, CTCs and ctRNA/exosomes, respectively. Albeit rare, these studies displayed noteworthy relevance, demonstrating the capacity to investigate questions related to the biology underlying analytes release that could not be explored via translational research with human samples. Translational, clinical and technological sectors of liquid biopsy may benefit from basic research and should take note of some important findings generated by these studies. Overall, results underscored the need to intensify the efforts to conduct future studies on liquid biopsy in basic research with new preclinical models.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms23105343